Expression and prognostic relevance of CD44v6 in stage I non-small cell lung carcinoma

Situ, Dongrong; Long, Hao; Lin, Peng; Zhu, Zhihua; Wang, Jiang; Xu, Zuojun; Xie, Zeming; Rong, Tiehua

doi:10.1007/s00432-010-0771-5

Cited by 26 publications

(27 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study demonstrated that expression of CD44 might serve as a functional marker for ROS-resistant tumor progenitor cells (Ishimoto et al, 2011). These findings are consistent with previous studies and showed that overexpression of CD44 in tumors correlates with an increased capacity of resistance to radiation therapy and an increased risk of local recurrence (Situ et al, 2010;de Jong et al, 2010;Kokko et al, 2011).…”

Section: Intrinsic Survival Mechanismssupporting

confidence: 81%

The Role of Cancer Stem Cells in Tumor Radioresistance

Kurth¹,

Peitzsch²,

Baumann³

et al. 2014

Cancer Stem Cells

View full text Add to dashboard Cite

Section: Intrinsic Survival Mechanismssupporting

confidence: 81%

The Role of Cancer Stem Cells in Tumor Radioresistance

Kurth¹,

Peitzsch²,

Baumann³

et al. 2014

Cancer Stem Cells

View full text Add to dashboard Cite

“…In contrast, metaplastic squamous epithelium in the proliferating basal layers of the bronchi displays increased immunoreactivity for CD44, implying that the malignant transformation of squamous cells is closely associated with CD44 expression. However, CD44 expression is generally low in lung adenocarcinoma [11,12], and this difference is probably attributable to the heterogeneous histological origin of lung adenocarcinoma.…”

Section: Discussionmentioning

confidence: 92%

Expression of Novel CD44st and MMP2 in NSCLC Tissues and Their Clinical Significance

Zhang

Hai

et al. 2017

Oncol Res Treat

View full text Add to dashboard Cite

Background: Abnormal expression of some CD44 molecules in tumor tissues can induce the degradation of the extracellular matrix, and is closely associated with axillary lymph node metastasis, angiogenesis, cancer progression, and drug resistance. Patients and Methods: We measured and confirmed the expression of CD44st and MMP2 mRNAs and proteins in the cancer tissues and adjacent normal tissues of postoperative non-small cell lung cancer (NSCLC) patients with either adenocarcinoma (n = 72) or squamous cell carcinoma (n = 53) using quantitative reverse transcription polymerase chain reaction, gene sequencing, and immunohistochemical analysis. Results: CD44st and MMP2 expression were closely associated with the histopathological classification, lymph node metastasis, and TNM stage of the tumors, and the difference was statistically significant (p < 0.05). The median overall survival (OS) for the high CD44st expression group was 30.52 months (95% confidence interval (CI) 24.02-36.15); for the low expression group it was 43.23 months (95% CI 31.81-52.02) (p = 0.020). The median OS for the high MMP-2 expression group was 30.53 months (95% CI 26.69-33.31); for the low expression group it was 40.06 months (95% CI 33.55-46.45) (p = 0.022). Conclusion: The rates of CD44st and MMP2 expression were higher in squamous cell carcinomas than in adenocarcinomas, were closely associated with lymph node metastasis and TNM stage, and affected patients' prognoses.

show abstract

“…In the progression of squamous cell carcinoma, metaplastic squamous epithelium develops through the replacement of ciliated epithelium by bronchial basal cells, and metaplastic epithelium was reported to show a strongly positive expression of CD44v6. Although CD44v6 has also been shown in bronchoalveolar carcinomas, Situ et al [19] reported that the rate of high CD44v6 expression in bronchoalveolar carcinomas was only 15.4%. These findings raise the possibility that CD44v6 may play an important role in the histogenesis of lung carcinoma.…”

Section: Discussionmentioning

confidence: 99%

Immunohistochemical Expression and Serum Levels of CD44 as Prognostic Indicators in Patients with Non-Small Cell Lung Cancer

et al. 2016

View full text Add to dashboard Cite

Background/Objectives: CD44 is often expressed in various types of tumor cells and involved in a number of biological behaviors of malignancy. The present study focused on the clinical significance of the expression of CD44st and CD44v6 in non-small cell lung cancer (NSCLC). Methods: The cohort consisted of 261 consecutive patients who had undergone complete resection of NSCLC. CD44 expression was evaluated in surgical specimens by immunohistochemical staining. Serum CD44 levels were determined using a sandwich ELISA (enzyme-linked immunosorbent assay). Results: In the immunohistochemical analysis, significant correlations were observed between CD44 expression and clinicopathological factors such as the T factor, N factor, pathological stage, and histological type. The 5-year survival rates according to CD44v6 expression were 65.8 and 80.6% in the higher and lower expression groups, respectively (p = 0.0053). According to ELISA, the group with higher expression of serum CD44v6 also showed a significantly more unfavorable prognosis than the lower expression group (p = 0.014). According to multivariate analysis using these significant variables, serum CD44v6 level was found to be an independent prognostic factor (p = 0.048). Conclusions: CD44v6 overexpression and higher serum CD44v6 levels were found to be significantly unfavorable prognostic factors.

show abstract

Expression and prognostic relevance of CD44v6 in stage I non-small cell lung carcinoma

Abstract: CD44v6 might be correlated with histogenesis of NSCLC, and its decreased expression may be an adverse prognostic indicator for the patients with stage I NSCLC, especially for those with stage IB diseases. Patients of this subgroup might need adjuvant therapy additionally.

Cited by 26 publications

References 30 publications

The Role of Cancer Stem Cells in Tumor Radioresistance

The Role of Cancer Stem Cells in Tumor Radioresistance

Expression of Novel CD44st and MMP2 in NSCLC Tissues and Their Clinical Significance

Immunohistochemical Expression and Serum Levels of CD44 as Prognostic Indicators in Patients with Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About